Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
58.84
+1.30 (+2.26%)
Streaming Delayed Price
Updated: 1:29 PM EDT, Apr 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
April 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
↗
March 27, 2026
This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
↗
March 13, 2026
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
Via
The Motley Fool
Topics
Regulatory Compliance
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner
↗
February 26, 2026
Via
Chartmill
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
↗
March 13, 2026
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
↗
March 13, 2026
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
March 12, 2026
Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon...
Via
Finterra
Topics
ETFs
Intellectual Property
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 10, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’
↗
March 09, 2026
Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.
Via
Stocktwits
Xenon Pharmaceuticals Announces Proposed Public Offering
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Top stock movements in today's session.
↗
March 09, 2026
Via
Chartmill
Monday's session: top gainers and losers
↗
March 09, 2026
Via
Chartmill
Gapping stocks in Monday's session
↗
March 09, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 09, 2026
Via
Chartmill
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
↗
February 23, 2026
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Via
The Motley Fool
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
↗
February 23, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
↗
February 23, 2026
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
↗
February 23, 2026
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
↗
February 23, 2026
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
↗
February 14, 2026
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Via
The Motley Fool
Topics
Regulatory Compliance
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
↗
February 14, 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
January 16, 2026
As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
